SPYRAL HTN-ON MED study presents initial data on renal denervation system


Medtronic has announced first-ever-data from the SPYRAL HTN-ON MED Study. Initial study results found statistically significant and clinically important blood pressure reductions in hypertensive patients prescribed anti-hypertension medications treated with the Symplicity Spyral renal denervation (RDN) system with no major adverse safety events out to six months. The Late-Breaking Trial data, presented at the 2018 EuroPCR Annual Meeting in Paris, France, was published simultaneously in The Lancet

At six months, patients randomised to the renal denervation procedure experienced an average 9mmHg drop in 24-hour mean systolic ambulatory blood pressure (ABPM), resulting in a 7.4mmHg difference compared to patients in the sham control arm (p=0.005). For RDN patients, 24-hour mean diastolic ABPM also declined 6mmHg, which is 4.1mmHg lower than the sham control arm (p=0.029).

Likewise, average office systolic blood pressure (OBP) in patients in the RDN arm declined 9.4mmHg—a 6.8mmHg difference from the sham control arm (p=0.021), and the diastolic OBP declined 5.2mmHg, a 3.5mmHg difference from the sham control arm (p=0.048).

“Data from the SPYRAL HTN-ON MED study is important for the clinical community and for patients with hypertension as it represents a typical scenario of managing uncontrolled hypertension patients, prescribed up to three blood pressure medications,” said David Kandzari, director of interventional cardiology and chief scientific officer at Piedmont Heart Institute in Atlanta, USA, co-principal investigator in the SPYRAL HTN-ON MED study, and member of the Medtronic Executive Committee that designed and oversees the SPYRAL HTN Global Clinical Program. “With these new results, mirroring those of the parallel SPYRAL HTN-OFF MED trial, we have convincing evidence at six months showing the continued safety and efficacy of RDN in both the presence and absence of blood pressure medication.”

The SPYRAL HTN-ON MED Study patient cohort was prescribed a stable regimen of up to three anti-hypertensive medications, including diuretics, calcium channel blockers, ACE /ARB inhibitors or beta blockers. Similar to recent studies of uncontrolled hypertension, drug testing indicated that adherence to prescribed anti-hypertensive medication was inadequate as only about 60 percent of patients were found to be taking medications as prescribed. Medication adherence remains a challenge in controlling hypertension in patients resulting in intermittent blood pressure control that can lead to an increased risk for cardiovascular events.

Additional analysis of the cyclical hourly changes in blood pressure demonstrated that the blood pressure lowering effects of renal denervation were distributed throughout the day and, importantly, throughout the nighttime period when blood pressure control is even more critical due to higher risks of adverse events like heart attack and stroke caused by hypertension. Blood pressure during sleep is the most significant predictive marker of cardiovascular disease morbidity and mortality, and reduction in asleep blood pressure is associated with highly significant reduction of cardiovascular disease risk.

“We are encouraged by these data showing the procedure may enable a blood pressure lowering effect 24 hours a day. RDN is essentially ‘always on’ even when the effect of medications may be subsiding between doses,” said Raymond Townsend, M.D., director of the Hypertension Program at the Hospital of the University of Pennsylvania, a professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania, and co-principal investigator in the trial. Townsend is a member of the Medtronic Executive Committee that designed and oversees the SPYRAL HTN Global Clinical Program. “These data also show that treatment with RDN in the main renal artery and branches with the Spyral System can help reduce blood pressure.”

Propelled by the momentum of the “ON” and “OFF MED” trials, the global SPYRAL HTN clinical program has now moved into its final pivotal phase.

“These positive outcomes, taken together with the already presented OFF MED data, and the recent initiation of our SPYRAL HTN Pivotal Trial, are strong indicators that RDN may one day play a significant role in helping to address the hypertension epidemic that more than one billion patients face around the world,” said Dave Moeller, vice president and general manager of the Coronary and Renal Denervation business, which is part of the Cardiac and Vascular Group at Medtronic.

The clinical program utilises the Medtronic next-generation renal denervation technology, composed of the flexible, 6Fr guide catheter compatible, Symplicity Spyral Multi-Electrode Renal Denervation Catheter and Symplicity G3 Renal Denervation RF (radiofrequency) Generator.


Please enter your comment!
Please enter your name here